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1. Introduction 
Human immunodeficiency virus (HIV) is a major challenge in the medical fraternity 
worldwide. According to the UNAIDS report on the global AIDS epidemic, in 2004 it had 
affected more than 42 million people, and of these 25 million resided in the sub-Sahara 
Africa (UNAIDS, 2004 & Bhigjee, 2005).  
This virus has no cure; the lives of the infected patients can only be prolonged using lifelong 
highly active antiretroviral (ARV) therapy (HAART). HAART has been proven to suppress 
HIV-1 viral replication continuously thus reducing mortality and morbidity in treated 
patients. It has further been proven that HAART is only highly effective if prescribed in 
combination of more than 2 drugs. However these drug combinations can be presented with 
potential drug-drug interactions (DDIs) an important cause of adverse drug reactions 
(ADRs) (Highleyman, 2007).  
DDIs are well-recognised causes of adverse drug effects (ADEs) (Bates et al., 1995). 
According to Juurlink et al. (2003), DDIs do cause particularly important type of adverse 
drug event because they are often predictable based on previous reports, clinical studies, 
and an understanding of pharmacological principles.  
According to Johnson et al. (1999), DDIs are classified as an important category of ADEs. 
Drug interactions result in undesirable modification of the action of one or more 
concurrently administered agents. The interaction may cause treatment failure, an increased 
pharmacologic effect, or a toxic effect, which may be fatal. Because DDIs usually have a 
specific time course (i.e., onset and duration), they are more predictable (and preventable) 
then ADRs (adverse drug reactions). Bates et al. (1999) state that Preventable DDIs account 
for about one third of ADEs but incur about one half of the total ADE costs.  
In HIV-infected patients, the introduction of HAART has led to reduced morbidity and 
mortality in treated patients (Egger et al., 2002). However, in a substantial proportion of 
patients, the effectiveness of HAART has not been sufficient due to occurrence of virological 
failure and immunological decay (Bartlett et al., 2001). All this has been due to failure to 
determine drug interactions and prevention of toxic effects. (Boffito et al., 2005).   
The possible causes of DDIs include drug combinations, lack of communication between the 
prescribers and medical history, increase in the number of newly marketed drugs and 
polypharmacy. Specific patients who are risk for DDIs include the elderly, people living 
with HIV/AIDS. Patients with HIV are more at risk for the virus because they are treated  
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using HAART which consist of at least three agents with the risk rising from 13% in patients 
taking two drugs to 82% in those taking seven drugs or more (Sanderson, 2005). 
The main focus in this abstract will be on the pharmacological aspects of DDIs between 
ARVs. The topics to be covered in this chapter will include: 
1. The concept of DDIs. 
2. The different types of DDIs. 
3. Drug-drug interactions rating systems and their significance levels. 
4. The possible causes of DDIs. 
5. Patients that are at risk for DDIs. 
6. The pharmacological aspects of DDIs between ARVs. 
7. The role of pharmacists in preventing DDIs in clinical practice and; 
8. Recommendations on the clinical management of DDIs. 
9. Conclusion. 
2. Concept of DDIs 
The term drug-drug interactions can be defined as “the pharmacological or clinical response to 
the administration of a drug combination different from that anticipated from the known effects of the 
two agents when given alone” (Tatro, 2009). As described by Tatro (2009), the effect of a DDI 
may be one of the following: 
 Antagonism, such as a loss of blood pressure control by clonidine when tricyclic 
antidepressants are added to a regimen.  
 Synergism, as an example of which is the increased anticoagulant effect resulting from 
administering salicylates and warfarin.   
 Idiosyncratic, such as the possible though rare severe effects that have been associated 
with patients concurrently receiving pethidine and monoamine oxidase inhibitor 
(Jankel & Fitterman, 1993).  
3. Different types of DDIs 
According to Seden et al. (2009), DDIs may arise due to the pharmacokinetics or 
pharmacodynamics of administered compounds. DDIs can be classified as pharmacokinetic 
or pharmacodynamics (Young, 2005; Cohen et al., 2002) or pharmaceutical (Hall, 1986).  
3.1 Pharmaceutical interactions 
Pharmaceutical interactions occur when two drugs are given together, e.g., in an infusion, or 
when a drug reacts with the infusion solution. While it is necessary to be aware of this type 
of interaction, it is relatively uncommon (Hall, 1986). 
3.2 Pharmacokinetic interactions 
Pharmacokinetic interactions may be defined as those interactions in which the disposition 
of the first drug is altered by the second drug or precipitant drug. As a result, the effect of 
the first drug is either diminished or increased. Pharmacokinetic interactions are divided 
into those that affect (Swart & Harris, 2005; Young, 2005; Cohen et al., 2002): 
 Drug absorption: An example of this interaction is when didanosine containing an 
aluminium-magnesium antacid buffer, is administered with ciprofloxacin, the metallic 
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ions in the buffer may chelate with ciprofloxacin, resulting in subtherapeutic blood 
levels of ciprofloxacin (Sahai et al., 1993). 
 Drug binding: This was illustrated by in vivo work which showed that methadone 
concentrations were decreased when administered with ritonavir, due to displacement 
of methadone from plasma binding sites (Piscitelli & Gallicano, 2001). 
 Drug metabolism: An example of this kind of interaction is between PIs and NNRTIS that 
act as inhibitors or inducers of cytochrome P450 (CYP450). Ritonavir is the most potent 
CYP450 and therefore the most likely to interact with other drugs such as amiodarone, 
cisapride or pethidine. Likewise efavirenz induces the metabolism of indinavir and 
saquinavir by reducing their plasma concentrations (Piscitelli & Gallicano, 2001).   
 Excretion: In this case, the NRTIs may have additive or synergistic adverse effects, so if 
for example stavudine is administered with zalcitabine or didanosine, because these 
drugs are eliminated primarily by the kidney peripheral neuropathy caused by 
stavudine (Lee & Henderson, 2001). 
 Transport system: One case report demonstrated a 48% decrease in valproic acid 
concentration after a patient had been started on lopinavir/ritonavir-based regimen. 
This interaction was likely to be due to the ability of ritonavir to induce valproic acid 
metabolism via glucuronidation (Sheehan et al., 2006). 
The result of pharmacokinetic DDIs may be an increase or decrease in the concentration of 
the drug at the site of action. The mechanism most common is drug metabolism. 
3.2.1 Drug metabolism interactions 
Drugs are metabolised by two types of reactions: phase 1 reactions that involve oxidation, 
reduction or hydrolysis in which drugs are turned into more polar compounds and phase 11 
reactions that involve coupling drugs with some other substance (e.g. glucuronic acid) to 
make (usually) inactive compounds (Cohen et al., 2002). These reactions make drugs more 
easily excretable. Drug metabolism interactions can increase or decrease the amount of drug 
available by inhibition or induction of metabolism (Cohen et al., 2002). 
3.2.1.1 Enzyme induction 
Enzyme induction frequently affects phase 1 oxidation, which requires the presence of the 
reduced form of nicotinamide adenine dinucleotide phosphate (NADPH) and the haem-
containing protein cytochrome P450. Enzyme inducers like carbamazepine, phenytoin, 
phenobarbital, PIs and NNRTIs, increase the activity of the microsomal enzymes 
(cytochrome P450 isoenzyme), increasing the rate of metabolism and excretion. One study 
reported that there was a decreased metabolism and subsequent toxicity of carbamazepine 
when concomitantly administered with ritonavir (Bates & Herman, 2006; Young, 2005). A 
case study reported of a patient who was prescribed ritonavir with midazolam 
concomitantly, and developed extreme sedation and possibly respiratory depression due to 
the inhibition of midazolam metabolism.  
3.2.1.2 Enzyme inhibition 
Enzyme inhibitors inhibit the microsomal enzymes (cytochrome P450 isoenzymes), 
decreasing the rate of metabolism and excretion of other drugs that are metabolised by these 
same enzymes (Cohen et al., 2002). Examples of these drugs are PIs and delavirdine 
presenting drug interactions with statins because they are metabolised by the same enzyme 
(Geletko & ZuWallack, 2001). These drugs begin to accumulate in the body and toxicity may 
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develop within 2 to 3 days. The clinical significance of the enzyme inhibition interaction 
depends on the extent to which serum levels rise. Some drugs may have additive or 
synergistic adverse effects. For example, zidovudine may cause anaemia and neutropnenia, 
so drugs causing bone marrow suppression should be prescribed with caution if used 
concomitantly (Matheny et al., 2001). Another example of this metabolism was the 
administration of simvastatin with saquinavir/ritonavir, the interaction leading to increased 
levels of simvastatin by more than 3000% (Fichenbaum et al., 2002b). This could put the 
patient at risk for adverse effects like myalgias, rhabdomyolysis, elevated creatinine 
phosphokinase and hepatic dysfunction (Dube et al., 2003). 
3.2.2 Cytochrome P450 isoenzymes 
Cytochrome P450 is a large family of related isoenzymes of which about 30 have been 
identified. The most frequently involved in drug interactions are CYP3A4 and CYP2D6. 
There are many drugs that are metabolised by these cytochrome P450 isoenzymes including 
ARVs (Clarke et al., 2008). Drugs may be metabolised by more than one cytochrome 
isoenzyme. For example, the majority of PIs and NNRTIs and antidepressants are substrates 
for, and can inhibit or induce the CYP450 system and have the potential to cause clinical 
drug interactions including serotonin syndrome, a potential fatal complication. According to 
Swart and Harris (2005) it is of value to know which particular isoenzymes are responsible 
for the metabolism of a specific drug as this makes it possible to predict with which other 
drugs it may possibly interact. 
3.3 Pharmacodynamic interactions 
Pharmacodynamic interactions are those where the effects of one drug are changed by the 
presence of another drug at its site of action, without alterations in the concentrations of 
either drug (Young, 2005; Cohen et al., 2002). Sometimes one drug competes directly with 
another for particular receptors, but often the reaction is more indirect and involves the 
interference with physiological mechanisms, making pharmacodynamic interactions more 
difficult to classify than pharmacokinetic interactions (DeVane as quoted by Delafuente, 
2003). There are four basic subdivisions as quoted by Swart and Harris (2005):  
 Additive or synergistic interactions and combined toxicity 
 Antagonistic or opposing interactions 
 Interactions due to changes in drug transport mechanisms 
 Interactions due to disturbances in fluid and electrolyte 
3.3.1 Mechanisms of drug-drug interactions 
Drugs interact with one another through various mechanisms which include altered 
absorption, altered distribution, altered metabolism and altered elimination. 
3.3.1.1 Altered absorption 
Drug interactions can occur where one drug changes the absorption characteristics of 
another drug. The binding of one drug to another causes changes in gastric pH, and changes 
in gastrointestinal motility and can cause these drug interactions (Cohen et al., 2002). One 
example is that of didanosine which contains an aluminium-magnesium antacid buffer. 
When administering didanosine with ciprofloxacin, the metallic ions in the buffer may 
chelate concomitantly with ciprofloxacin resulting in subtherapeutic levels of the antibiotic 
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(Sahai et al., 1993). It is therefore recommended that the two drugs be administered at 
different times. Absorption of many drugs, such as delavirdine, atazanavir, aspirin, 
ciprofloxacin, and digoxin, can be significantly impaired by concurrent administration of 
antacids by a variety of mechanisms (Fulco et al, 2006). 
3.3.1.2 Gastrointestinal motility 
A mechanism of DDIs that may go unrecognised is where one drug changes the 
gastrointestinal transit time. In doing so, the pharmacokinetics of   not altering the transit 
time can be changed, leading to changes in the drug’s pharmacological actions. Drugs with 
anticholinergic properties and opioids will slow gastrointestinal motility, while drugs, such 
as metoclopramide and laxatives will increase gastric emptying and gastric transit and 
generally increase the rate of absorption (Benet et al., 1990).  
3.3.1.3 Altered gastric pH 
Drugs that change the normal pH of the stomach can affect absorption characteristics of 
other drugs. This is an essentially important point, considering the widespread use of 
proton pump inhibitors, although only a few clinically relevant interactions have been 
identified (e.g. ketoconazole) (Delafuente, 2003). The results of data in a study done by 
O’Connor-Semmes et al. (2001) suggested that the elderly may be more sensitive to the 
increase in gastric pH compared to younger adults.  
According to Piscitell and Gallicano (2001), when didanosine is administered with indinavir, 
changes in pH may significantly alter drug absorption of indinivarir because of an increase 
in pH due to the didanosine buffer. It is therefore recommended that didanosine and 
indinavir be administered at least one hour apart. 
It has been reported by Fulco et al. (2006) and Tran et al. (2001) that acid-suppressive therapy 
with histamine-2 (H2) blockers, proton pump inhibitors or antacids can cause a decrease in 
the absorption of some PIs. This is due to changes in the pH of the gastrointestinal tract. PIs 
like atazanavir, fosamprenavir, tipranavir have been found to have significant interactions 
with acid-suppressive therapy that require intervention due to the potential for virological 
failure from inadequate ARV concentration (Fulco et al., 2006).   
3.3.1.4 Altered distribution 
The most common DDI affecting drug distribution is alteration in protein binding. This type 
of interaction occurs when there is competitive inhibition for protein binding sites. This 
allows for the unbound fraction of the drugs to be increased, and it is the free fraction that is 
responsible for pharmacological activity (Young, 2005). Most of the clinically significant 
interactions involve drugs that are highly protein bound and have a narrow therapeutic 
index. An example of this is when the cytidine analogue lamivudine inhibits 
phosphorylation of another cytidine analog, zalcitabine, resulting in high incidence of 
toxicities.  Therefore such combinations should be avoided (Young, 2005). 
An example of this DDI is when zidovudine and stavudine are co-administered, the two 
NRTIs do compete for cellular thymidine kinase, the enzyme that is responsible for the 
monophosphorylation of both drugs to nucleotides. The inhibitory effect impairs the 
efficacy of stavudine when combined with zidovudine (Havril et al., 2000).    
3.3.1.5 Altered metabolism 
3.3.1.5.1 Cytochrome P450 isoenzyme 
Most of the clinically important types of pharmacokinetic DDIs are those altering a drug’s 
metabolism. Many elderly patients, but not all, have underlying impaired CYP450 
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metabolising capability. According to Flockhart and Tanus-Santos (2002), six CYP450 
isoenzymes that have been identified to be involved in oxidative metabolism of most 
commonly used drugs are: CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4. 
Interactions involving the CYP450 enzymes are often due to either inhibition of an 
isoenzyme, leading to increased blood or tissue concentrations of the substrate, or 
induction of an isoenzyme, causing enhanced metabolism and lower substrate 
concentrations (Delafuente, 2003:137). According to Johnson et al. (1999) enzyme 
inhibition is the mechanism most often responsible for life-threatening interactions.32 Such 
interactions have been observed when zalcitabine is combined with stavudine or 
didanosine producing severe peripheral neuropathy, pancreatitis, and lactic acidosis 
(Simpson & Tagliati, 1995).    
Induction of certain CYP450 isoenzymes, for example CYP2C9/19 by lopinavir/ritonavir 
and nelfinavir was reported by Honda et al. (1999) that it could lead to an increase in the 
matabolism of antiepileptic drugs like phenytoin, a norrow therapeutic index drug. The 
reduction in the anticonvulsant serum concentration could lead to seizures.    
3.3.1.5.2 Cytochrome P450 inhibition 
Competitive binding at the enzyme’s binding site between two drugs is often responsible for 
inhibition of a drug’s metabolism. The onset of CYP450 inhibition depends on the inhibiting 
drug’s half-life. For drugs with short half-lives, enzyme inhibition occurs quickly and 
clinically significant interactions can be apparent within 1 or 2 days (Cheng et al., 2009). 
Inhibition of CYP450 is also dose-dependent. Higher doses of an inhibitory drug will cause 
greater amounts of competitive inhibition than lower doses. Although sufficient data are not 
available to help in clinical situations as stated by Delafuente (2003), knowing the CYP450 
enzymes involved in a drug’s metabolism can be used to predict and avoid clinical 
problems resulting from drug interactions. 
All currently marketed PIs – atazanavir, amprenavir, fosamprenavir, indinavir, lopinavir, 
nelfinavir, ritonavir and saquinavir (Young, 2005) – and the NNRTI delavirdine inhibit 
CYP3A4 (Piscitelli & Gallicano, 2001) decrease the hepatic clearance of CYP3A4 substrates 
and increase their plasma levels.   
3.3.1.5.3 Cytochrome P450 induction 
The onset of enzyme induction is usually longer than that of enzyme inhibition (Chapron, 
2001). Enzyme induction is dependent on the half-life of the synthesis of new CYP450 
isoenzymes and is dependent on the half-life of the inducing drug. Like inhibition of 
CYP450 enzymes, shorter half-life drugs will have a shorter onset of induction. A drug with 
half-life, such as phenobarbital, may take one week before enzyme induction is seen. 
Drugs often involved in induction of CYP450 isoenzymes are carbamazepine, phenytoin, 
phenobarbital, primidone, and rifampicin (Clarke et al., 2008). Aging may impair enzyme 
induction, but this is not a universal finding as stated by Chapron (2001). 
Of the ARVs, the NNRTIs nevirapine and efavirenz induce CYP3A4, thus increasing the 
hepatic clearance of CYP3A4 substrates and decreasing their plasma levels (Piscitelli & 
Gallicano, 2001). Other ARVs like PIs induce CYP450 isoenzymes, and it has been reported 
that drugs like phenytoin, rifampin, carbamazepine, phenobarbital, and dexamethasone can 
increase the hepatic clearance and therefore decrease plasma concentrations of the PIs 
(Lesho & Gey, 2003).     
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3.3.1.5.4 Altered renal elimination 
Many drugs and drug metabolites are excreted in the urine via renal tubular secretion. Two 
drugs can compete for the same active secretion sites in the tubule allowing for decreased 
elimination and potentially toxic serum concentrations (Lesho & Gey, 2003). Alteration in 
urine pH can also affect drug elimination. Alkalinisation of the urine will decrease 
elimination of drugs that are weak bases and decreases in urine pH will increase their 
elimination. Acidification of the urine will decrease renal elimination of drugs that are weak 
acids (Hasten, 1995). 
This mechanism happens in interactions that alter drug bioavailability by decreasing it and 
these are commonly found in PIs. The reason is that PIs induce CYP450 isoenzymes, so 
drugs like phenytoin, rifampin, carbamazepine, phenobarbitone, and dexamethasone can 
increase the hepatic clearance, thereby decreasing plasma concentrations of the PIs (Lesho & 
Gey, 2003). All this result in increase in toxicity of the drugs (Lesho & Gey, 2003). In the 
elderly as stated by Delafuente (2003), more common and potentially more significant are 
DDIs that affect renal function. Glomerular filtration rates decline with advanced aging. To 
compensate for this physiologic change, a compensatory production of vasodilatory renal 
prostaglandins occurs (Delafuente, 2001). However, according to Swedko et al. (2003) in frail 
elderly patients, serum creatinine concentrations may be very misleading, often in the 
normal range despite poor renal function.  
4. DDIs rating system: significance levels 
Most rating systems as employed by Tatro (2009) and De Maat et al. (2004) indicate: 
 major significance, 
 moderate significance; and 
 minor significance. 
4.1 Major significance: level 1 
Significance level 1 indicates a major contradiction or a drug interaction that requires very 
careful monitoring. According to Strain et al. (2002b) the effects are potentially life-
threatening or capable of causing permanent damage. The clinician needs to document why 
he or she is prescribing this combination, and the medical necessity to use both drugs 
concomitantly only if there is no alternative or the potential benefit outweighs the risk. Drug 
combinations producing an interaction with a significance level 1 are combinations that 
result in serious and potentially life-threatening adverse effects such as arrhythmia, 
respiratory depression and/or death (Winston & Boffito, 2005).  
Obviously, if this combination is to be used the drug(s) in question must be prescribed with 
an explanation as to the need for their concomitant use and must be preceded by very 
cautious monitoring. Documentation of the clinician’s awareness of the potential serious – 
level 1 – interaction should be accomplished at the time of prescribing this potentially 
dangerous combination. In addition, it is obligatory to alert the other health care providers’ 
of the potential interactions and adverse outcomes which they could expect. Obviously, the 
optimum choice, if possible, is to use an alternative medication to avoid significance level 1 
interactions (Strain et al., 2002a).     
4.2 Moderate significance: level 2 
With significance level 2, the effects may cause deterioration in a patient’s status. Additional 
treatment, hospitalisation or extension of hospital stay may be necessary (Strain et al., 
www.intechopen.com
 
Understanding HIV/AIDS Management and Care – Pandemic Approaches in the 21st Century 
 
288 
2002b). The potential interaction must also be documented and the clinical outcome(s) must 
be monitored carefully so that unacceptable, pernicious reactions are halted as soon as 
possible. According to Strain et al. (2002b) it is essential that the clinician document that the 
potential drug interactions were considered when using this combination. It is also essential 
to alert the patient’s health care providers to the potential interactions so that they are 
observed early in their course. 
4.3 Minor significance: level 3 
As stated by Strain et al. (2002b) the effects are usually mild. Consequences may be 
bothersome or unnoticeable, but should not significantly affect the therapeutic outcome. 
Additional treatment is usually not required (Tatro, 2005 & Sewester, 2001). According to 
Strain et al. (2002a) significance level 3 does not preclude the use of a specific drug, but 
clinical decision making requires acknowledging if the adverse reactions (e.g. nausea and 
rash) might be precluded by choosing an alternative drug. The potential interaction and its 
mechanism(s) needs documentation in the patient’s medical chart and the patient’s health 
care providers need to be informed. 
Another rating system is employed by Drug Interaction Facts which utilises 5 point 
significance classification scheme (Tatro, 2009) and Facts and Comparisons (McEvoy, 2000) 
and they recommended the following:  
 Avoid combination: risk always outweighs benefit. 
 Usually avoid combination: use combination only under special circumstances. 
 Minimise risk: take action as necessary to reduce risk. 
 No action needed: risk of adverse outcomes appears small. 
 No interaction: evidence suggests no interaction. 
5. Possible causes of DDIs 
5.1 Drug combinations 
Drug combinations of interacting drugs are among the major causes leading to DDIs (Seden 
et al., 2009). Drug combinations are more common in an elderly population using many 
drugs (Bjőrkman et al,. 2002). A large proportion of these combinations are likely to be part 
of a normal drug regimen. In a study done by Bjőrkman et al. (2002), in DDIs most of the 
drug combinations increased the risk of ADRs and lowered therapeutic effects as stated by 
Seymour and Routledge (1998). In all potential DDIs, 50% of the combinations could result 
in an adverse drug reaction and 50% in a suboptimal therapeutic effect. However, 
combination ARV treatment is a potent and effective therapy for HIV infection (Pontali, 
2008). This is also a disadvantage because ARV drugs frequently interact amongst 
themselves and other drugs as was identified by KatendeKyenda et al (2007). Since some of 
these drug combinations have negative effects, more attention must be focused on detecting 
and monitoring patients using such combinations and could also be addressed by dose 
adjustment. 
5.2 Lack of communication and medication history 
Communication between emergency departments and primary care physicians often does 
not occur (Beers et al., 1990), and primary care physicians do not take down medication 
histories optimally and therefore, the physicians responsible for follow-up may be unaware 
of the changes made in therapy. 
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Emergency department physicians do not routinely screen for potential drug interactions 
due to unavailability of a medication history. In a study by Beers et al. (1990) it was stated 
that groups of patients at higher risk of drug complications, the elderly and those taking 
multiple medications, did not appear to receive more cautious care. Neither the physician’s 
record nor the instructions given to the patient indicated that prescribing physicians 
recognised the potential adverse reactions that were introduced. There is need for physians 
to screen for interactions. A patient’s advanced age or a long list of medications should 
cause the physicians to be more reticent in prescribing. Fewer medications should be given 
to the elderly and to high medication users. 
5.3 Increase in number of newly marketed drugs 
There is a considerable number of newly marketed drugs with a growing number of 
possible combinations. Complex disease states often require the concurrent use of these 
drug combination therapies so as to be highly effective (Bergk et al., 2004). Nevertheless, as 
supported by Merlo et al. (2001) multiple drug use is also associated with the occurrence of 
DDIs. Therefore the majority of these interactions can be compensated by dose adjustment 
or prevented by a well-considered sequence of administration (Bergk et al., 2004). The 
considerable number of newly marketed drugs with a number of possible combinations 
raises the need to support general practitioners with the pertinent information for careful 
approach to patients.  
5.4 Polypharmacy 
Polypharmacy, the use of two or more medications by one patient, has become prevalent 
especially in elderly patients (Gaeta et al., 2002). Beers et al. (1990) in their study showed that 
those 65 years of age and older used an average of two to six prescribed medications and one 
to four non-prescribed medications per day. The frequency of polypharmacy in the elderly 
increases the incidence of adverse drug reactions and interactions, and it is the most significant 
contributing factor for DDIs. Patient’s past medical history and medication has to be evaluated 
by the physicians. According to Seden et al. (2009), polypharmacy is largely unavoidable for 
patients receiving ARVs in both the developed and developing world and resource-poor 
setting, with life-long treatment and change of drug combinations along the way.    
6. Patients at risk for DDIs 
Patients that are at risk for DDIs are discussed in this section with specific reference to the 
elderly and the HIV/AIDS patients. 
6.1 The elderly 
The incidence of adverse drug reactions and interactions in the elderly has been reported to 
be two to three times the incidence in younger patients (Nolan & O’Malley, 1998). 
According to Sloan (1992), this increased risk for the elderly may be related to impaired 
organ reserve capacity, multiorgan dysfunction, and altered pharmacokinetics and 
pharmacodynamics.   
6.2 People living with HIV/AIDS 
The HIV infection is treated by using HAART, which involves a regimen of at least three 
agents to be effective (Seden et al., 2009). In a study on DDIs in general medical patients, 
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Sanderson (2005) found that the risk of DDIs rose from 13% in patients taking two drugs to 
82% in patients taking seven drugs or more. 
7. Pharmacological aspects of DDIs between ARVs 
DDIs are a serious complication of taking multiple medications and account for 3% to 5% of 
all hospital medication errors (Leape et al., 1995). According to Clarke et al. (2008), the 
consequences of drug interactions vary ranging from drug toxicities to therapeutic failures, 
or loss of effectiveness and can significantly affect a patient’s clinical outcome. Of particular 
concern are drug interactions in patients infected with HIV who are receiving HAART 
because it involves a regimen of a least three agents (Seden et al., 2009).  
HAART has revolutionised the management of HIV-1 infection and  the ARV therapy has 
improved steadily in terms of efficacy, tolerability, and dosing convenience since the advent 
of HAART in 1995 (Chandwani & Shuter, 2008). HAART consists of four classes that are 
available for ARV therapy: (Nucleoside/nucleotide reverse transcriptase inhibitors 
(N(t)RTIs; non-nucleoside reverse transcriptase inhibitors (NNRTIs); protease inhibitors 
(PIs); and a fusion inhibitor). The strongly recommended regimen based on the existing 
efficacy data, is either NNRTI-based or PI-based HAART (Yeni at al., 2004). 
7.1 Clinically significant drug interactions associated with Highly Active Antiretroviral 
Therapy 
One of the most challenging issues faced by health care providers treating patients with 
HIV-1 infection is the complex problem of DDIs associated with HAART (Seden et al., 2009; 
Clarke et al., 2008; Pontali, 2007; Cohen et al., 2002). The guidelines for the initial treatment of 
HIV infection recommend the use of at least three ARVs (Bartlett et al., 2006a), each of which 
is  associated with significant drug interactions (DHHS, 2003). Drug interactions associated 
with HIV medications can be classified into those that alter the pharmacokinetics and those 
that alter pharmacodynamics (Seden et al., 2009).  
Pharmacokinetic drug interactions result in a change in pharmacokinetic parameters, such 
as the area under the curve (AUC), which measures drug exposure, peak concentration 
(Cmax), through concentration or half-life (Young, 2005; Cohen, 2002). Pharmacodynamic 
interactions result in alterations in the pharmacologic activity of the medication; not causing 
a change in the pharmacokinetic (Young, 2005; Cohen, 2002). The most common drug 
interactions in HIV medicine are pharmacokinetic interactions as a result of a change in the 
absorption, distribution and  metabolism and  the result of the  concurrently administered 
medication (Piscitelli & Gallicano, 2001).   
7.2 Influence of cytochrome P450 (CYP450) on DDIs in HIV  
The cytochrome P450 enzyme system is responsible for the biotransformation of drugs from 
active to inactive metabolites that are readily excreted by the body.  DDIs are more common in 
PIs and NNRTIs (Seden et al., 2009; Winston & Boffito, 2005; Young, 2005; Cohen et al., 2002). 
Of the numerous isoenzymes of CYP450 that have been identified, the ones responsible for 
elimination of drugs used in HAART are CYP3A, CYP1A2, and CYP2D2 (Clarke et al., 2008). 
7.3 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs & NtRTIs) 
The NRTIs are valuable ARV agents in the treatment of HIV infection because they 
constitute the “backbone” of highly active ARV therapy regimens (Waters & Boffito, 2007). 
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Drug interactions associated with NRTIs and NtRTIs are few because these drugs are not 
metabolised by the CYP450 system (Clarke et al., 2008). However, drug interactions may still 
occur within these drugs as was demonstrated by Katende-Kyenda et al. (2008a). One of the 
few pharmacodynamic interactions encountered in HIV medicine occurs, for example  with 
co-administered zidovudine and stavudine, since both drugs are thymidine analogues and  
they can compete for the same phosphorylation site in the growing chain of HIV DNA, 
resulting in an antagonistic, pharmacodynamic interaction (Piscitelli & Gallicano, 2001). It is 
therefore recommended that these two drugs never to be combined.  
The use of didanosine (ddl) is complicated by drug interactions (Cohen et al, 2002). It is a 
buffered tablet form containing magnesium and calcium to improve systemic absorption. It, 
however, interacts with certain antibiotics like ciprofloxacin, tetracycline and therefore,  to 
minimise the interaction, didanosine  should be administered at least two hours after or six 
hours before the fluoroquinolone (Knupp & Barbhaiya, 1999). Concurrent use of didanosine-
buffered tablets may also impair the absorption of the PI atazanavir, since atazanavir 
requires an acidic environment for absorption (Product Information Videx EC, 2003). To 
minimise the interaction, patients should take a didanosine-buffered tablet two hours after 
or one hour before taking atazanavir. 
The most significant didanosine drug interaction reported occurs when didanosine is used 
concurrently with the NrRTI tenofovir. The didanosine AUC increases by 60% and therefore 
it is recommended that in patients receiving these two drugs concurrently and weighing > 
60 kg, the didanosine dosage should be reduced from 400 mg to 250 mg once daily or from 
250 mg to 200 mg in patients who weigh less than 60 kg (Young, 2005). For severely 
underweight patients, the dose should be further reduced to 125mg once daily (Faragon & 
Piliero, 2004). All patients receiving concurrent tenofovir and didanosine should be closely 
monitored for didanosine -related toxicities such as pancreatitis, hyperlactatemia, and lactic 
acidosis, regardless of didanosine dosage adjustments. 
7.4 Non-Nucleoside Reverse Transciptase Inhibitors (NNRTIs) 
Drugs in this group are prone to drug interactions because they are extensively metabolised 
via CYP3A4 and can act as either inducers or inhibitors of CYP3A4. Nevirapine and 
efavirenz are inducers of CYP3A4, while delavirdine is an inhibitor of CYP3A4 (Pfister et al., 
2003). Therefore, when one of these drugs is combined with a drug that is also metabolised 
by CYP3A4, a drug interaction may occur (Clarke et al., 2008).  
Nevirapine presents with numerous drug interactions, being a CYP3A4 inducer, and drug 
interactions associated with it lead to an increase in metabolism and reduced concentration 
of the co-administered drug. For example, when nevirapine is concurrently given with 
methadone, withdrawal symptoms may occur as a result of reduced methadone levels 
(Pinzanni et al., 2000). Efavirenz is a potent inducer of CYP3A4 in vivo. Like the PIs, EFV is 
extensively metabolised primarily by the CYP3A4 (Pfister et al., 2003).  
The induction properties of efavirenz can result in reduced concentrations of concurrently 
administered drugs that are metabolised by CYP3A4 and it is therefore contraindicated with 
midazolam, triazolam and ergotamine derivative since there is a potential for increased 
drug concentrations of these medications and associated toxicity (Product Infomation 
Sustiva, 2003). Efavirenz, as a potent inducer of CYP3A4 is suggested to have a potential 
interaction with lopinavir and ritonavir, both of which inhibit CYP3A4. This interaction was 
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assessed in a parallel group study in which PI-experienced, NNRTI-naive, HIV-infected 
patients received different doses of these agents (Young, 2005).    
7.5 Non-Nucleoside Reverse Transcriptase and Protease Inhibitors Interactions 
When predicting potential drug interactions, it is important to know which P450 isoenzyme 
is responsible for the metabolism of a drug. Drug interactions between NNRTIs and PIs are 
common as was observed in a study by Katende-Kyenda (2008b), as all currently available 
agents in these two classes are metabolised mainly by the 3A4 isoenzyme of the CYP450 
system (Fichtenbaum & Gerber, 2002). NNRTIs and PIs also inhibit or induce CYP3A4, 
decreasing or increasing hepatic clearance and, thereby, increasing or decreasing plasma 
levels, respectively, of drugs metabolised by CYP3A4. Therefore, depending primarily on 
the potency of each NNRTI or PI as an inhibitor or inducer of CYP3A4 and on the substrate 
affected, each one has a different drug interaction profile.  
All currently marketed PIs – atazanavir, amprenavir, fosamprenavir, indinavir, lopinavir, 
nelfinavir, ritonavir, and saquinavir – and the NNRTI delavirdine inhibit CYP3A4 (Piscitelli 
& Gallicano, 2001). According to Von Moltke et al. (1998), ritonavir is the most potent 
CYP3A4 inhibitor and, consequently, has the most drug interactions, while amprenavir, 
indinavir, lopinavir, and nelfinavir appear to inhibit CYP3A4 equally, and saquinavir with 
the lowest  inhibitory effect.  
7.6 Effect of Protease Inhibitors on Nucleoside Analogues 
The nucleoside analogue reverse transcriptase inhibitor, tenofovir, does not appear to inhibit 
CYP3A4 isoenzyme significantly  and, like most inhibitors, is excreted by the kidneys. 
Tenofovir, unlike other NRTIs, is associated with several drug interactions, particularly a 
bidirectional effect (i.e. agent can alter plasma levels of the other) with atazanavir, while 
atazanavir raises plasma levels of tenofovir (Holder, 2003).    
Indinavir does not alter the pharmacokinetics of zidovudine, stavudine or lamivudine 
(Perry & Belfour, 1996:928). This is because the optimal absorption of indinavir requires a 
normal (acidic) gastric pH whereas an acid medium rapidly degrades didanosine, which is 
formulated with buffering agents to increase the pH. Therefore the administration of 
indinavir and didanosine should be separated by at least 1 hour to avoid an interaction 
mediated by altered drug absorption (Perry & Balfour, 1996). 
7.7 Effect of Non-Nucleoside Reverse Transciptase Inhibitors on Nucleoside 
Analogues 
Nevirapine is a potent and selective non-competitive inhibitor of reverse transcriptase (De 
Maat et al., 2003). It does not compete with template or nucleoside triphosphates, and 
therefore a significant interaction would not be expected. Nevirapine may reduce plasma 
zidovudine concentrations by 25% but does not influence plasma concentrations of 
didanosine or zalcitabine (Murphy & Montaner, 1996). 
NRTIs, unlike NNRTIs and PIs, are not metabolised by the hepatic CYP3A4 ezyme system 
and – the exception of zidovudine and abacavir - undergo renal rather than biliary excretion. 
Zidovudine undergoes hepatic glucuronidation and abacavir is metabolised in the liver by 
alcohol dehydrogenase (Barry et al.,1999). Therefore, there is little potential for interaction 
between NRTIs and NNRTIs or between NRTIs and PIs. In addition, the NRTI class as a 
whole has fewer drug interactions than the NNRTI and PI classes have. 
www.intechopen.com
 
Drug-Drug Interactions as a Challenge in the Treatment of HIV/AIDS 
 
293 
7.8 Protease inhibitor interactions 
The PIs are extensively metabolised by the cytochrome P450 (CYP) enzymes present in the 
liver and small intestine (Winston & Boffito, 2005). Therefore drug interactions involving PIs 
will occur largely as a result of enzyme induction or enzyme inhibition (Barry et al., 1999). 
Some PIs can alter metabolism and thus the plasma concentration of other PIs, creating 
complex drug interactions when a second PI is added to HAART. According to Van 
Heeswijk et al. (2001), additionally, favourably positive DDIs can increase the exposure to 
PIs, allowing the use of lower doses at reduced dosing frequencies with fewer dietary 
restrictions.  
Protease inhibitors have differing affinities for the CYP3A4 isoenzyme. The most potent 
inhibitor of CYP3A4 is ritonavir (Cooper et al., 2003), whereas the least potent is saquinavir. 
CYP3A4 inhibition associated with indinavir, nelfinavir, and amprenavir, and atazanavir 
tends to be intermediate. Ritonavir is often the most likely medication in the PI class to 
cause drug interactions because in addition to its CYP3A4 inhibition, it also inhibits CYP2D6 
and induces CYP1A2 and CYP2C9 (Clarke et al., 2009). However, ritonavir is often used to 
enhance the pharmacokinetic parameters of co-administered PIs like indinavir (Kappelhoff 
et al., 2005), due to its potent inhibition of their metabolism by CYP3A4 (Zeldin & 
Petruschke, 2004).  
The use of boosted double PI regimen is presented with complex unexpected 
pharmacokinetic interactions (Winston & Boffito, 2005). Therefore combinations like 
tipranavir/ritonavir with others must be avoided because such combinations have shown to 
significantly reduce plasma concentrations of saquinavir, amprenavir and lopinavir (Boffito 
et al., 2005). Another interesting interaction that was observed by Boffito et al. (2005) was 
with the boosted double combinations of atazanavir/saquinavir/ritonavir. Saquinavir levels 
are enhanced in this regimen further than when dosed with ritonavir alone, thus suggesting 
a role for this as a once daily regimen.   
8. Role of pharmacists in preventing DDIs in clinical practice 
Although the number of clinically relevant DDIs is probably low, DDIs may be responsible 
for a substantial number of hospital admissions. Therefore the pharmacist is responsible for 
preventing the use of unsafe or non-effective drug regimens. Specifically, pharmacists 
should avoid the dispensing of combinations of drugs that may cause serious DDIs (Becker 
et al., 2005).  
Many drug interactions can be avoided or managed safely if adequate time and precautions 
are taken by a patient’s pharmacist. Having the pharmacist provide patient counselling on 
the use of prescription and non-prescription medication, disease state(s), and the safety of 
concurrent use of herbal products plays a major role in avoiding drug interactions (Brown, 
2004).   
According to Lien and Lien (1994), many patients visit more than one doctor for their 
different diseases and receive more than one drug at a time, and often doctors are unaware 
of all the medications their patients are taking and the risks to which their patients are 
exposed when treated with multiple drugs. Since pharmacists in the community setting or 
hospital, are the most accessible health care providers, they are able to intervene when faced 
with potential drug interactions that may occur during patients’ multiple drug therapy. 
Adverse DDIs are the major cause of morbidity and mortality. Cancer patients, for example, 
are particularly at high risk of such interactions because they commonly receive multiple 
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medications, including cytotoxic chemotherapy, hormonal agents and supportive care drugs 
(Blower et al., 2005). Increased awareness by pharmacists of the potential for drug 
interactions will allow health care providers to minimise the risk by selecting appropriate 
drugs and also by monitoring for signs of interaction.  
According to Pezella (2005), in 2000, the number of patient deaths attributable to ADRs in 
the United States of America, was estimated to be 218 000 annually. More than 51% of 
approved drugs in the market in 2009 may have serious side-effects not detected before 
marketing approval. Therefore health plans and pharmacy benefit managers must work 
together to take effective steps to increase ADR monitoring and reporting and to proactively 
avoid ADRs through pharmacy management tools.    
9. Recommendations regarding management of level 2 ARV DDIs in clinical 
practice  
The overall review revealed that most DDIs are identified between ARVs interacting at level 
2 as identified by Tatro guidelines. Therefore the following recommendations can be 
formulated to manage these DDIs, based on the standard treatment guidelines for ARVs.  
 Patients must be told the importance of consulting their doctors before using over- the 
counter drugs that might interact with their prescribed ARVs; 
 The prescriber should always check for potential DDIs then prescribing any 
concomitant drug for a patient who is on ARV therapy; 
 Drug level monitoring of concurrent patients’ medications should be done; 
 While DDIs involving HIV drugs are essentially unavoidable, many can be managed 
through dosage adjustments as recommended by McNicholl &  Coffey, (2007 & 2009) 
and McNicholl, (2009).  
10. Conclusion 
This chapter dealt with drug-drug interactions as a challenge presented to healthcare 
providers in the management of HIV/AIDS. This worldwide epidemic can be managed 
using HAART which according to the recommended treatment guidelines, three or more 
drugs have to be prescribed. However some these combinations present with DDIs, the 
major cause of adverse drug events. DDIs can nevertheless be managed accordingly either 
by switching the drug combinations or by dosage adjustments. It is therefore the role both 
prescribers and specifically the pharmacists to identify the DDIs and working in 
collaboration manage them.  
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